.
MergerLinks Header Logo

New Deal


Announced

PFM Health Sciences led a $100m Series C round in Caresyntax.

Financials

Edit Data
Transaction Value£71m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private

digital surgery platform

Minority

Completed

Digital Services

Single Bidder

Venture Capital

United States

Acquisition

Friendly

Private Equity

Cross Border

Synopsis

Edit

PFM Health Sciences led a $100m Series C round in Caresyntax, with participation from Optum Ventures, Intel Capital, Lauxera Capital Partners, Vesalius Biocapital, Arno Capital, Rezayat Investments, IPF Partners, the Relyens Group, and Surgical.AI. "Operating rooms need to perform as effectively and efficiently as possible, and this is especially true now to make up for the surgical backlog driven by the pandemic. With better technology to safely automate surgical pathways while generating decision-grade real-world evidence, we will improve health care decision-making, mitigate surgical risks, and advance high-value medical technology," Dennis Kogan, Caresyntax Founder and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US